Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Surgical Devices

See what CB Insights has to offer

Founded Year




Total Raised


Date of IPO


About Corvita

Developer of small vascular grafts synthetic vascular grafts used to replace or bypass damaged or diseased arteries. Grafts are manufactured using Corvita's a proprietary polycarbonate urethane material which can closely replicate the strength and elasticity of human arteries. The product line, called Corvita Grafts, includes: (1) the Peripheral Graft, used to replace diseased arteries primarily in the leg, (2) the AV Access Graft, an arterial to venous graft implanted in the arm to draw and return blood during hemodialysis, and (3) the Endovascular Graft, introduced via minimally invasive surgical techniques and designed to treat damaged arteries. U.S. clinical trials of the Peripheral Graft began in September 1992 a request for pre-market approval (PMA) will be filed in mid-1995. Clinical trials of the AV Access Graft began in the U.S. in March 1994 and Corvita expects to file a PMA in late 1995. Clinical testing of the Endovascular Graft is slated to begin in mid-1995.

Corvita Headquarter Location

8210 Northwest 27th Street

Miami, Florida, 33122,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.